Could this new treatment really reverse celiac disease? – Innovation Toronto
via Northwestern University Feinberg School of Medicine
New technology may be applicable to other autoimmune diseases and allergies
Results of a new phase 2 clinical trial using technology developed at Northwestern Medicine show it is possible to induce immune tolerance to gluten in individuals with celiac disease. The findings may pave the way for treated celiac patients to eventually tolerate gluten in their diet.
After treatment with the technology, the patients were able to eat gluten with a substantial reduction in inflammation. The results also show a trend toward protecting patients’ small intestine from gluten exposure.
The findings will be presented as a late-breaking presentation Oct. 22 at the European Gastroenterology Week conference in Barcelona, Spain.
The technology is a biodegradable nanoparticle containing gluten that teaches the immune system the antigen (allergen) is safe. Thenanoparticle acts like a Trojan horse, hiding the allergen in a friendly shell, to convince the immune system not to attack it.
Beyond celiac disease, the finding sets the stage for the technology — a nanoparticle containing the antigen triggering the allergy or autoimmune disease — to treat a host of other diseases and allergies including multiple sclerosis, type 1 diabetes, peanut allergy, asthma and more.
The technology was developed in the lab of Stephen Miller, professor of microbiology and immunology at Northwestern University Feinberg School of Medicine, who has spent decades refining the technology.
“This is the first demonstration the technology works in patients,” said Miller, the Judy Gugenheim Research Professor of Microbiology and Immunology.“We have also shown that we can encapsulate myelin into the nanoparticle to induce tolerance to that substance in multiple sclerosis models, or put a protein from pancreatic beta cells to induce tolerance to insulin in type 1 diabetes models.”
When the allergen-loaded nanoparticle is injected into the bloodstream, the immune system isn’t concerned with it, because it sees the particle as innocuous debris. Then the nanoparticle and its hidden cargo are consumed by a macrophage, essentially a vacuum-cleaner cell that clears cellular debris and pathogens from the body.
“The vacuum-cleaner cell presents the allergen or antigen to the immune system in a way that says, ‘No worries, this belongs here,’” Miller said. “The immune system then shuts down its attack on the allergen, and the immune system is reset to normal.”
In the celiac disease trial, the nanoparticle was loaded with gliadin, the major component of dietary gluten, found in cereal grains such as wheat. A week after treatment, the patients were fed gluten for 14 days. Without treatment, celiac patients eating gluten developed marked immune responses to gliadin and damage in their small intestine. Celiac patients treated with the COUR nanoparticle, CNP-101, showed 90% less immune inflammation response than untreated patients. By stopping the inflammatory response, CNP-101 showed the capacity to protect the intestines from gluten related injury.
There currently is no treatment for celiac disease.
“Doctors can only prescribe gluten avoidance, which is not always effective and carries a heavy social and economic toll for celiac patients,” Miller said.
About 1% of the population has celiac disease,a serious autoimmune disease in which the ingestion of gluten leads to damage in the small intestine. When people with celiac disease eat gluten (a protein found in wheat), their body mounts an immune response that attacks the small intestine.
Autoimmune diseases generally can only be treated with immune suppressants that provide some relief, but undermine the immune system and lead to toxic side-effects. CNP-101 does not suppress the immune system but reverses the course of disease.
“Celiac disease is unlike many other autoimmune disorders because the offending antigen (environmental trigger) is well known — gluten in the diet,” said Dr. Ciaran Kelly, professor of medicine at Harvard Medical School and director of the Celiac Center at Beth Israel Deaconess Medical Center. “This makes celiac disease a perfect condition to address using this exciting nanoparticle induced immune tolerance approach.”
Kelly, who will be presenting the research abstract in Barcelona, has been working with Miller to apply the technology and define the therapeutic approach to treating celiac disease.
The nanotechnology was licensed to COUR Pharmaceuticals Co., a biotech based in Northbrook and co-founded by Miller. COUR developed CNP-101, which was granted Fast Track status from the U.S. Food and Drug Administration, and brought the therapy to patients in collaboration with Takeda Pharmaceuticals. Takeda will announce Tuesday they have acquired an exclusive global license to develop and commercialize this investigational medicine for celiac disease.
“Given the license by Takeda, COUR will focus on clinical programs in peanut allergy and multiple sclerosis in the near term and broaden even further over time,” said John J. Puisis, president and chief executive officer of COUR.
The Latest on: Celiac disease
October 22, 2019 – New treatment may reverse celiac disease: New technology may be applicable to other autoimmune diseases and allergies Science DailyExciting Breakthrough Hold Promise For Those With Celiac Disease CBS New YorkPossible Celiac Disease Nanotechnology Treatment Breakthrough Revealed NewsweekRevolutionary New Treatment May Allow Those With Celiac Disease To Safely Eat Gluten Study FindsTakeda picks up Cour’s celiac treatment, promising $420M in biobucks FierceBiotechView full coverage on Google News
October 22, 2019 – Woman Discovers Her Celiac Disease with 23andMe Gene Test Celiac Disease and Gluten-Free Diet Support – Celiac.com
October 7, 2019 – Risk of Autoimmune Disorders in Treated Celiac Disease Patients Celiac Disease and Gluten-Free Diet Support – Celiac.com
September 30, 2019 – Do Celiac families really need 2 toasters? Risk of gluten transfer in common-cooking activities may be lower than previously thought Science Daily
October 10, 2019 – Kristen Bell Says She Woke Up With A Gluten Intolerance 2 Months Ago Women’s Health
via Google News
The Latest on: Celiac disease
Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to prevent gluten induced immune activation in patients with …
The results of a clinic trial suggest medical nanotechnology could lead to new effective treatments for celiac disease and a rash of other ailments. The treatment, called CNP-101/TAK-101, was …
The results of a clinic trial suggest medical nanotechnology could lead to new effective treatments for celiac disease and a rash of other ailments. The treatment, called CNP-101/TAK-101, was …
NEW YORK (CBSNewYork) – There’s an exciting breakthrough to treat celiac disease. It’s a way to stop the painful and destructive attacks triggered by eating wheat. CBS2’s Dr. Max Gomez explains how it …
NEW YORK (CBSNewYork) – There’s an exciting breakthrough to treat celiac disease. It’s a way to stop the painful and destructive attacks triggered by eating wheat. CBS2’s Dr. Max Gomez explains how it …
Celiac disease patients in a phase 2 clinical trial were able to eat gluten with substantially less inflammation after the treatment with the technology. Celiac disease is a serious autoimmune disease …
Celiac disease patients in a phase 2 clinical trial were able to eat gluten with substantially less inflammation after the treatment with the technology. Celiac disease is a serious autoimmune disease …
Takeda Pharmaceutical today further bolstered its pipeline in one of its key therapeutic areas, gastroenterology, by acquiring an exclusive global license to develop and commercialize COUR …
Takeda Pharmaceutical today further bolstered its pipeline in one of its key therapeutic areas, gastroenterology, by acquiring an exclusive global license to develop and commercialize COUR …
A phase 2 clinical trial using a new technology show it is possible to induce immune tolerance to gluten in individuals with celiac disease. After treatment with the technology, the patients were able …
A phase 2 clinical trial using a new technology show it is possible to induce immune tolerance to gluten in individuals with celiac disease. After treatment with the technology, the patients were able …
Based on positive data from a mid-stage study, Takeda Pharmaceutical Company (NYSE:TAK) has secured a global license to COUR Pharmaceutical Development Company’s CNP-101 (TAK-101), an intravenously …
Based on positive data from a mid-stage study, Takeda Pharmaceutical Company (NYSE:TAK) has secured a global license to COUR Pharmaceutical Development Company’s CNP-101 (TAK-101), an intravenously …
Results of a new phase 2 clinical trial using technology developed at Northwestern Medicine show it is possible to induce immune tolerance to gluten in individuals with celiac disease. The findings …
Results of a new phase 2 clinical trial using technology developed at Northwestern Medicine show it is possible to induce immune tolerance to gluten in individuals with celiac disease. The findings …
Oct 22 (Reuters) – Takeda Pharmaceutical Co Ltd: * TAKEDA ACQUIRES LICENSE FOR FIRST-IN-CLASS CELIAC DISEASE THERAPY FROM COUR PHARMACEUTICALS FOLLOWING POSITIVE PHASE 2A PROOF-OF-CONCEPT STUDY * …
Oct 22 (Reuters) – Takeda Pharmaceutical Co Ltd: * TAKEDA ACQUIRES LICENSE FOR FIRST-IN-CLASS CELIAC DISEASE THERAPY FROM COUR PHARMACEUTICALS FOLLOWING POSITIVE PHASE 2A PROOF-OF-CONCEPT STUDY * …
While there are instances when it would just go away, there are cases when it would mean a more serious health problem. Have you heard about celiac disease? It is an ailment that affects the digestive …
While there are instances when it would just go away, there are cases when it would mean a more serious health problem. Have you heard about celiac disease? It is an ailment that affects the digestive …
via Bing News